“Lebrikizumab Dosed Every 8 Weeks As Maintenance Provides Long-Lasting Response in Patients With Moderate-to-Severe Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s601, https://doi.org/10.25251/14pn6v71.